LongBio Pharma develops targeted therapies for allergy and complement diseases, utilizing proprietary platforms such as SunDoma™ and InCibitor™ to enhance treatment efficacy. The company aims to provide patients with affordable, high-quality biomedicines that address unmet clinical needs in these specialized areas.
Funding
Funding not disclosed
Founders
Product
Problem
Allergy and complement diseases represent significant unmet clinical needs, often requiring specialized and costly treatments. Existing therapies may lack optimal efficacy or have limited accessibility, leaving many patients without affordable, high-quality biomedicines.
Solution
LongBio Pharma develops innovative drugs for allergy and complement-mediated diseases, leveraging proprietary technology platforms to enhance treatment outcomes. Their approach focuses on creating affordable and accessible biomedicines that address the underlying mechanisms of these conditions. By targeting specific pathways involved in allergic reactions and complement system dysregulation, LongBio aims to provide more effective and tailored therapeutic options for patients. The company's pipeline includes a range of novel drug candidates designed to improve the quality of life for individuals affected by these diseases.
Target Audience
The primary target audience includes patients suffering from allergy and complement diseases, as well as healthcare providers specializing in these therapeutic areas.
Features
- SunDoma™ platform for developing targeted therapies
- InCibitor™ platform for complement-related diseases
- NeXine™ platform (details not provided, but listed as a platform)
- LP-003: Pipeline candidate (details not provided)
- LP-005: Pipeline candidate (details not provided)
- CMG901: Investigational drug in Phase I clinical trial for advanced solid tumors
- CM310: Investigational drug in Phase III clinical trial for moderate-to-severe atopic dermatitis